NF-κB as a therapeutic target in chronic lymphocytic leukemia

Abstract

Importance of the field: NF-κB includes a family of transcription factors that play a critical role in the biology of normal lymphocytes and it is aberrantly activated in chronic lymphocytic leukemia (CLL) cells. Here, we review the role of constitutive NF-κB activation in CLL pathogenesis and its potential as a therapeutic target for CLL treatment.

Areas covered in this review: This review highlights the different strategies reported to inhibit NF-κB signaling in CLL cells. They include both IκB kinase inhibitors and several natural compounds that act at different steps of the pathway.

What the reader will gain: Targeting NF-κB leads to apoptosis of CLL cells, corroborating the role of NF-κB in the survival and clonal expansion of these tumoral cells. Moreover, several studies confirmed a synergistic effect between NF-κB inhibitors and other antitumoral agents and that inhibition of NF-κB could overcome the microenvironmental protection of CLL cells.

Take home message: NF-κB is a relevant target in CLL and inhibitors of this prosurvival pathway, alone or in combination, represent a novel therapeutic strategy for the treatment of CLL patients.

Keywords::

• apoptosis
• chronic lymphocytic leukemia
• IKK inhibitor
• NF-κB

Notes

This box summarizes key points contained in the article.